September 21, 2009 — Antigenics Inc. (NASDAQ: AGEN) announced that the company has signed an amended and restated license agreement for the use of the QS-21 adjuvant in a vaccine under development by JANSSEN Alzheimer Immunotherapy, a company which has acquired substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program (AIP).
“Alzheimer's disease is the sixth-leading cause of death in the United States, and the incidence of this disease is expected to rise globally.” said Garo H. Armen, PhD, chairman and CEO of Antigenics. “Today's announcement underscores the importance of QS-21, which is being tested in multiple indications by our licensees, including four Phase 3 programs in lung cancer, malaria, melanoma and an undisclosed infectious disease. QS-21 is enabling a new generation of vaccines to be developed and is expected to become a significant contributor to Antigenics' future royalty income, with the first vaccine potentially on the market by 2011.”... Antigenics' Press Release -
